Ocular implant made by a double extrusion process

Details Ocular implant made by a double extrusion process Ocular implant made by a double extrusion process

2008-07-15

2011-11-01

Foley, Shanon A (Department: 1648)

Drug, bio-affecting and body treating compositions

Preparations characterized by special physical form

Implant or insert

C623S006560

Reexamination Certificate

active

08048445

ABSTRACT:
The invention provides biodegradable implants sized for implantation in an ocular region and methods for treating medical conditions of the eye. The implants are formed from a mixture of hydrophilic end and hydrophobic end PLGA, and deliver active agents into an ocular region without a high burst release.

REFERENCES:
patent: 3986510 (1976-10-01), Higuchi et al.
patent: 4853224 (1989-08-01), Wong
patent: 4863457 (1989-09-01), Lee
patent: 4997652 (1991-03-01), Wong
patent: 5164188 (1992-11-01), Wong
patent: 5378475 (1995-01-01), Smith et al.
patent: 5443505 (1995-08-01), Wong et al.
patent: 5501856 (1996-03-01), Ohtori et al.
patent: 5766242 (1998-06-01), Wong et al.
patent: 5773021 (1998-06-01), Gurtler et al.
patent: 5824072 (1998-10-01), Wong
patent: 5869079 (1999-02-01), Wong et al.
patent: 6054485 (2000-04-01), Schwartz et al.
patent: 6217895 (2001-04-01), Guo et al.
patent: 6217911 (2001-04-01), Vaugn et al.
patent: 6309669 (2001-10-01), Setterstrom et al.
patent: 6369116 (2002-04-01), Wong et al.
patent: 6548078 (2003-04-01), Guo et al.
patent: 6586006 (2003-07-01), Roser et al.
patent: 6699493 (2004-03-01), Wong
patent: 6726918 (2004-04-01), Wong et al.
patent: 2003/0007992 (2003-01-01), Gibson et al.
patent: 2004/0137059 (2004-07-01), Nivaggioli et al.
patent: 0 052 916 (1981-07-01), None
patent: 0 430 539 (1990-11-01), None
patent: 0 488 401 (1991-11-01), None
patent: 0 488 401 (1991-11-01), None
patent: 0 654 256 (1994-02-01), None
patent: 0 654 256 (1994-02-01), None
patent: 430 539 (1994-10-01), None
patent: 654 256 (1995-05-01), None
patent: 0 992 244 (2000-04-01), None
patent: WO 95/13765 (1995-05-01), None
patent: WO 96/38174 (1996-12-01), None
patent: WO 97/26869 (1997-07-01), None
patent: WO 00/37056 (2000-06-01), None
patent: WO 02/43785 (2001-11-01), None
patent: WO 03/094888 (2003-05-01), None
patent: WO 2004/026106 (2004-04-01), None
patent: WO 2005/110362 (2005-04-01), None
Dohlman C. et al.,Treatment of corneal edema with a buried implant, Tr. Am. Acad. Opth. & Otol., Mar.-Apr. 1966, pp. 267-280.
Morita Y., et al.,Intravitreous delivery of dexamethasone sodium m-sulfobenzoate from poly(DL-lactic acid)implants, Biol. Pharm. Bull., Feb. 1998; 21(2): 188-90.
American Academy of Ophthalmology; Basic and Clinical Science Course: Intraocular inflammation and Uveitis Section 9, 2003-2004 57-80, 102-103, 152-156.
Apel et al.; A subconjunctival degradable implant for cyclosporine delivery in corneal transplant therapy; Current Eye Research; 1995; 659-667.
Bloch-Michel, Etienne;Opening Address: Intermediate Uveitis; Boke WRF, Manthey KF, Nussenblatt RB (eds):Intermediate Uveitis; Dev Ophthalmol; Basel, Karger; 1992, vol. 23; 1-2.
Boke WRF, Manthey KF, Nussenblatt RB (eds): Clinical Picture of Intermediate Uveitis ;Intermediate Uveitis; Dev Ophthalmol; Basel, Karger; 1992, vol. 23; 20-27.
Cheng et al.; Intravitreal Sustained-Release Dexamethasone Device in the Treatment of Experimental Uveitis;Investigative Ophthalmology&Visual Science; Feb. 1995, vol. 36, No. 2; 442-453.
De Jong et al.; New insights into the hydrolytic degradation of poly (lactic acid): participation of the alcohol terminum;Polymer42 (2001) 2795-2802.
Gould et al.; Fifty:fifty poly (DL glycolic acid-lactic acid) copolymer as a drug delivery system for 5-fluorouracil: a histopathological evaluation;Can J Ophthalmol, vol. 29, No. 4, 1994; 168-171.
Kwak et al.; Evaluation of the Retinal Toxicity and Pharmacokinetics of Dexamethasone After Intravitreal Injection;Arch Ophthalmol, vol. 110, Feb. 1992, 259-266.
Lee et al.; Drug delivery to the posterior segment; Chapter 25 ofPrinciples of vitreoretinal therapy, vol. 1, Part 1, 1989, 483-498.
Maurice, David M.; Micropharmaceutics of the Eye;Ocular Inflammation Ther., 1; 1983, 97-102.
Renfro et al.; Ocular Effects of Topical and Systemic Steroids;Dermatologic Clinics, vol. 10, No. 3, Jul. 1992, 505-512.
Ogden et al. editors; Retina—Basic Science and Inherited Retinal Disease vol. 1, St. Louis; CV Mosby.
Olsen et al.; Human Scleral Permeability—Effects of Age, Cryotherapy, Transscleral Diode Laser, and Surgical Thinning;Investigative Ophthalmology&Visual Science; Aug. 1995, vol. 36, No. 9, 1893-1903.
Park et al.; A new preparation method for protein loaded poly (D,L-lactic-coglycolic acid) Microspheres and protein release mechanism study;Journal of Controlled Release; 55 (1998), 181-191.
Tracy et al.; Factors affecting the degradation rate of poly (lactide-co-glycolide) Microspheres in vivo and in vitro;Biomaterials; 20 (1999), 1057-1062.
Schwartz, Bernard;The Response of Ocular Pressure to Corticosteroids; Ophthalmol. Clin. North Am., 6; 929-89.
Skalka et al.; Effect of Corticosteroids on Cataract Formation;Arch Ophthalmol; vol. 98, Oct. 1980, 1773-1777.
Ahmed, I., et al., Macular disorders: cystoid macular oedema, in: Yanoff, M., Duker, J.S., eds.,Ophthalmology, London: Mosby; 1999:34.
Akduman, L., et al., The early treatment diabetic retinopathy study, in: Kertes, P.S., Conway, M.D., eds,Clinical trials in ophthalmology: a summary and practice guide, Baltimore, MD: Lippincott Williams & Wilkins; 1998:15-35.
Bloch-Michel, E., (1992), Opening address: intermediate uveitis, inIntermediate Uveitis, Dev. Ophthalmol, W.R.F. Böke, et al. editors., Basel: Karger, 23:1-2.
Bodor, N., et al., (1992),A comparison of intraocular pressure elevating activity of loteprednol etabonate and dexamethasone in rabbits, Current Eye Research 11:525-30.
Böke, W., (1992), Clinical picture of intermediate uveitis, InIntermediate Uveitis, Dev. Ophthalmol.W.R.F. Böke et al. editors., Basel: Karger, 23:20-7.
Cheng, C.-K., et al., (1995),Intravitreal sustained-release dexamethasone device in the treatment of experimental uveitis, Invest. Ophthalmol. Vis. Sci. 36:442-53.
Clarkson, J.G., Central retinal vein occlusion, in:Retina, Ryan, S., Schachat, A.P., eds., 3rd ed. St. Louis, MO: CV Mosby; 2001, v2, chap 75:1368-1375.
Dick, J., et al., Macular edema, In:Retina, Ryan, S., Schachat, A.P., eds., 3rd ed. St. Louis, MO: CV Mosby; 2001, v2, Section 2 chap 57:967-979.
Fekrat, S., Finkelstein, D., The Central Vein Occlusion Study, in:Clinical trials in ophthalmology: a summary and practice guide, Kertes, P.S., Conway, M.D., eds., Baltimore, MD: Lippincott Williams & Wilkins; 1998:129-143.
Frank, R.N., Etiologic mechanisms in diabetic retinopathy, in: Retina, Ryan, S., Schachat, A.P., eds., 3rd ed. St. Louis, MO: CV Mosby; 2001, v2, Section 2, chap 71:1259-1294.
Gilman, A.G., et al., eds. (1990).Goodman and Gilman's: The Pharmacological Basis of Therapeutics. 8th Edition, Pergamon Press: New York, p. 1447.
Heller, Biodegradable Polymers in Controlled Drug Delivery, in:CRC Critical Reviews in Therapeutic Drug Carrier Systems, vol. 1., CRC Press, Boca Raton, FL (1987).
Jennings, T., et al.,Posterior sub-Tenon's injections of corticosteroids in uveitis patients with cystoid macular edema, Jpn J Ophthalmol 1988;32:385-391.
Jong, et al.,Polymer42:2795-2802 (2001).
Kwak, H.W. and D'Amico, D. J., (1992),Evaluation of the retinal toxicity and pharmacokinetics of dexamethasone after intravitreal injection, Arch. Ophthalmol. 110:259-66.
Lee, V.H.L., et al., Drug delivery to the posterior segment, in:Retina, T.E. Ogden and A.P. Schachat eds., St. Louis, MO: CV Mosby, 1989, chap 25:483-498.
Leopold, I.H.,Nonsteroidal and steroidal anti-inflammatory agents, in: Surgical pharmacology of the eye, Sears, M., Tarkkanen, A., eds., New York, NY, Raven Press; 1985:83-133.
Maurice, D.M., (1983).Micropharmaceutics of the eye, Ocular Inflammation Ther. 1:97-102.
Nauck, M., et al.,Corticosteroids inhibit the expression of the vascular endothelial growth factor gene in human vascular smooth muscle cells, Eur J Pharmacol 1998;341:309-315.
Olsen, T.W., et al. (1995),Human scleral permeability: effects of age, cryotherapy, transscleral diode laser, and surgical thinning, Invest. Ophthalmol. Vis. Sci. 36:1893-1903.
Orth, D., The branch vein occlusion study, in:Clinical trials in ophthalmology: A summary and practice guide, Kertes P, Conway M, eds., Baltimore, MD: Lip

Affiliated with

Also associated with

Rating

Ocular implant made by a double extrusion process does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Ocular implant made by a double extrusion process, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Ocular implant made by a double extrusion process will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4293151